Author + information
Antihypertensive therapy is effective to control blood pressure and prevent cardiovascular events, but further treatment for patients who cannot achieve goal BP with mono-therapy is still under dispute. Our study investigates the impacts of amlodipine, valsartan and their combination on blood pressure variability(BPV) and pulse wave velocity(PWV) to provide reference for clinical medication.
A total of 119 outpatients newly diagnosed essential hypertension or receiving low dose mono-therapy underwent a 10-week treatment. They were randomized into amlodipine 10mg group(n=40), valsartan 160mg group(n= 38), or amlodipine 5mg+valsartan 80mg (n=41). Demographic data and laboratory indicators were collected before and 10 weeks after the treatment. 24- hour ambulatory blood pressure and brachial ankle pulse wave velocity were also monitored.
all therapies reduce systolic and diastolic BP (p<0.05). 24-hour systolic BPV were significantly decreased in amlodipine and combination groups(3.55±2.57mmHg, 4.11±2.20mmHg vs 2.23±2.54 mmHg, p<0.05). The effects on diastolic BPV differ between different treatments. Three antihypertensive schemeslower PWV. Degree from strong to weak was followed by valsartan, combination and amlodipine[228.87±60.41 cm/s vs 152.49±49.25 cm/s vs 99.35±35.57 cm/s, p<0.01 ].
Theses results suggest that all further strategy can effectively control blood pressure, and the combination treatment is recommended in terms of BPV and PWV.